{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T01:24:32Z","timestamp":1786929872790,"version":"build-2736575974"},"reference-count":55,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Target Antitumor Ther"],"accepted":{"date-parts":[[2026,6,21]]},"abstract":"<jats:p xml:lang=\"en\">Breast cancer management increasingly hinges on decisions made in \u201cgrey zones\u201d where tissue sampling is scarce, and tumour biology evolves under therapeutic pressure. This narrative review synthesises evidence on how whole-body imaging biomarkers and circulating tumour DNA (ctDNA) can support response-adaptive pathways at the interface of surgical and systemic care. Four clinically actionable domains are discussed. (a) 16\u03b1-[18F]fluoro-17\u03b2-estradiol ([18F]FES) positron emission tomography\/computed tomography (PET\/CT) enables non-invasive, whole-body mapping of functional oestrogen receptor (ER) expression to address receptor discordance, heterogeneous metastases, and selection of endocrine-based strategies. (b) Human epidermal growth factor receptor 2 (HER2)-targeted PET (notably 89Zr-trastuzumab, with emerging alternatives) provides whole-body receptor assessment to uncover actionable HER2-positive disease despite HER2-negative primaries, informing anti-HER2 treatment selection when repeat biopsy is infeasible. (c) In triple-negative breast cancer treated with immune checkpoint inhibitors, 18F-fluorodeoxyglucose (18F-FDG) PET\/CT offers quantitative response and whole-body burden assessment but requires immunotherapy-aware interpretation (e.g., confirmation strategies for apparent early progression) to mitigate pseudoprogression and dissociated responses, while simultaneously visualising immune-related adverse events. (d) Pairing early metabolic change on FDG PET\/CT with ctDNA kinetics is presented as a biologically complementary approach for response monitoring and risk stratification, with potential to inform trial-embedded response-adaptive hypotheses, with ctDNA offering a rapid systemic trajectory and PET providing lesion-level localisation in heterogeneous or oligoprogressive disease. Overall, these tools add value only when linked to prespecified clinical questions and consensus actions; prospective studies are needed to validate standardised, outcome-improving response-adaptive algorithms that integrate imaging and liquid biopsy. Key implementation challenges include tracer availability, harmonised acquisition\/reconstruction, threshold definition, and avoiding overtesting. Near-term impact may be greatest in problem-solving and in trial-embedded decision rules that operationalise biomarker-guided care.<\/jats:p>","DOI":"10.37349\/etat.2026.1002398","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:35:38Z","timestamp":1786926938000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET\/CT under immunotherapy, and ctDNA kinetics"],"prefix":"10.37349","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3650-0587","authenticated-orcid":false,"given":"Jovana","family":"Zivanovic","sequence":"first","affiliation":[{"name":"Centre for Nuclear Medicine and PET, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-2094","authenticated-orcid":false,"given":"Jules","family":"Zhang-Yin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Clinique Sud Luxembourg, Vivalia, 6700 Arlon, Belgium; Department of Nuclear Medicine, Centre National PET, Centre Hospitalier de Luxembourg, L-1210 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2967\/jnumed.125.270763","article-title":"The Role of Estrogen Receptor-Targeted PET with 16\u03b1-","volume":"67","author":"Specht","year":"2026","journal-title":"J Nucl Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071919","article-title":"Head-to-Head Comparison between","volume":"11","author":"Piccardo","year":"2022","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231216093","article-title":"ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors","volume":"15","author":"You","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.240315","article-title":"Estrogen Receptor-targeted PET Imaging for Breast Cancer","volume":"312","author":"Zhou","year":"2024","journal-title":"Radiology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23435","article-title":"ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer","volume":"7","author":"Ulaner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11307-025-02015-2","article-title":"[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer","volume":"27","author":"Manohar","year":"2025","journal-title":"Mol Imaging Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15172139","article-title":"Could","volume":"15","author":"San\u00f2","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101644","article-title":"The Role of [","volume":"17","author":"Cuzzocrea","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01205-x","article-title":"[","volume":"15","author":"Xu","year":"2025","journal-title":"EJNMMI Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302486","article-title":"Clinical and economic outcomes of adding [18F]FES PET\/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US","volume":"19","author":"Munter-Young","year":"2024","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.2023S116","article-title":"18F-fluoroestradiol positron emission tomography in patients with breast cancer: a systematic review and meta-analysis","volume":"69","author":"Matushita","year":"2023","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01555-7","article-title":"Evaluation of tumour heterogeneity by","volume":"24","author":"Liu","year":"2022","journal-title":"Breast Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2967\/jnumed.120.244459","volume":"62","author":"Peterson","year":"2021","journal-title":"J Nucl Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.120.247882","article-title":"Head-to-Head Evaluation of","volume":"62","author":"Ulaner","year":"2021","journal-title":"J Nucl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1277","DOI":"10.1634\/theoncologist.2019-0096","volume":"24","author":"Liu","year":"2019","journal-title":"Oncologist"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1148\/radiol.2017162956","volume":"286","author":"Salem","year":"2018","journal-title":"Radiology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-16-2197","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1007\/s00259-015-3107-5","article-title":"Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy","volume":"42","author":"van Kruchten","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2967\/jnumed.115.172031","article-title":"Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET\/CT","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/RLU.0000000000001820","article-title":"89Zr-Trastuzumab PET\/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer","volume":"42","author":"Ulaner","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1007\/s00259-018-4099-8","volume":"45","author":"Bensch","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"Lindstr\u00f6m","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-018-4696-z","article-title":"Evaluation of [","volume":"169","author":"Dehdashti","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204980","volume":"15","author":"Linders","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2967\/jnumed.121.262940","article-title":"Use of","volume":"63","author":"Mortimer","year":"2022","journal-title":"J Nucl Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0082-6","article-title":"(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients","volume":"5","author":"Kurihara","year":"2015","journal-title":"EJNMMI Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using","volume":"59","author":"Ulaner","year":"2018","journal-title":"J Nucl Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/cbr.2018.2654","article-title":"Imaging of HER2 with [","volume":"34","author":"Massicano","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","author":"S\u00f6rensen","year":"2016","journal-title":"Theranostics"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2967\/jnumed.124.268931","article-title":"Quantitative [","volume":"66","author":"Mansur","year":"2025","journal-title":"J Nucl Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092620","article-title":"PET\/CT in Patients with Breast Cancer Treated with Immunotherapy","volume":"15","author":"Vaz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00259-024-06866-9","article-title":"The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective","volume":"52","author":"Filippi","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref34","first-page":"120","article-title":"Prognostic value of FDG PET\/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients","volume":"6","author":"Marinelli","year":"2016","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-015-3558-1","article-title":"Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET\/CT imaging","volume":"153","author":"Yue","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030637","article-title":"Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [","volume":"14","author":"Bouron","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/cam4.4522","article-title":"Heterogeneity derived from","volume":"11","author":"Xie","year":"2022","journal-title":"Cancer Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040723","article-title":"FDG-PET\/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST","volume":"11","author":"Vogsen","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199529","article-title":"FDG PET\/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST","volume":"13","author":"Depardon","year":"2018","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7508\/aojnmb.2016.04.002","article-title":"Predictive Ability of","volume":"4","author":"Kiyoto","year":"2016","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e1646","DOI":"10.1093\/oncolo\/oyae185","article-title":"18F-FDG PET\/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis","volume":"29","author":"Wu","year":"2024","journal-title":"Oncologist"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s00259-021-05489-8","article-title":"Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"49","author":"Roy","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14202312","article-title":"The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [","volume":"14","author":"Gelardi","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071249","article-title":"FDG-PET\/CT and Multimodal Machine Learning Model Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer","volume":"17","author":"Groheux","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.802579","article-title":"Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy","volume":"12","author":"Magbanua","year":"2022","journal-title":"Front Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1355887","article-title":"Circulating tumor DNA: from discovery to clinical application in breast cancer","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1634859","article-title":"Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review","volume":"15","author":"Easaw","year":"2025","journal-title":"Front Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00626-6","article-title":"Circulating tumor DNA validity and potential uses in metastatic breast cancer","volume":"10","author":"Amato","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/ijc.35292","article-title":"Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements","volume":"156","author":"Mouhanna","year":"2025","journal-title":"Int J Cancer"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57988-z","article-title":"Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15212718","article-title":"From Innovation to Application: Can Emerging Imaging Techniques Transform Breast Cancer Diagnosis?","volume":"15","author":"Hsu","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11111060","article-title":"Systematic Meta-Analysis of Computer-Aided Detection of Breast Cancer Using Hyperspectral Imaging","volume":"11","author":"Leung","year":"2024","journal-title":"Bioengineering (Basel)"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:35:41Z","timestamp":1786926941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":55,"URL":"https:\/\/doi.org\/10.37349\/etat.2026.1002398","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,16]]},"assertion":[{"value":"2026-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-16","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002398"}}